Proarrhythmic and antiarrhythmic effects of intravenous prostacyclin in XXXX .

@entity1 @entity1169 @entity1165 @entity591 @entity943
Prostacyclin (PGI2) has been shown to reduce the occurrence of experimental @entity943 . To assess potential beneficial effects in @entity1 , the electrophysiological action of PGI2 was studied in 16 non medicated @entity1 . The protocol used in incremental pacing and programmed stimulation in the right atrium and ventricle. This protocol and measurement of effective refractory periods (ERP) were performed before and during the injection of 2.5, 5 and 10 ng kg-1 min-1 of PGI2. The atrial functional refractory period decreased significantly (P less than 0.05); PGI2 had no influence on the occurrence of inducible non-sustained (NS) @entity591 and was responsible for the occurrence of 2 non-sustained @entity591 in 8 @entity1 with inducible atrial echo beats under basal conditions. Thirteen @entity1 did not have inducible @entity1165 ( @entity1165 ) under basal conditions. Non-sustained @entity1165 was induced after PGI2 in 4 of them but in only 1 of them after the administration of @entity1169 . Three @entity1 had inducible @entity1165 under basal conditions (1 non-sustained, 2 sustained @entity1165 ). PGI2 did not prevent the occurrence of @entity1165 (1 non-sustained, 1 sustained @entity1165 ), except in 1 @entity1 with ischaemic-related @entity1165 , who had non-sustained @entity1165 after PGI2. In conclusion, PGI2 does not seem to have a cardiac antiarrhythmic effect and may increase the atrial and ventricular repetitive response. This effect could be related to an increase of adrenergic tone.
